IOC Banned Drugs and their Effects on the Cardiovascular System

  • C. Montemartini
  • G. Iraghi


Doping is defined as the administration or intentional use of substances external to the body, however they are introduced, or as measures taken by an athlete before or during a sporting event with the aim of artificially and illegally improving his sporting Performance [18]. Physical Performance is physiologically activated by means of the intense Stimulation of all or nearly all the organs or apparatuses of the human body. This is particularly true for the cardiocirculatory System. There is no activity which does not require the immediate Support of blood circulation, and so any substance capable of ergotropically modifying the physical Performance has to act by stimulating the cardiocirculatory system. Many of them are normal deposit-releasing chemical mediators of cardiovascular ergotropic Stimuli, that are usually synthesised and metabolised in the human body, but the majority are substances which are not present physiologically but can indirectly stimulate active cardiac and vessel receptors. In the first group, the Stimuli are physiologically similar to those which normally occur during training sessions designed to improve gradually the responses of neuromodellers and so their artificial introduction into the circulation differs from normal physiology only in terms of their sudden effect and the lack of preparation on the part of the body as a whole; the substances in the second group have a reflex action which is accompanied by the large number of side effects which are themselves toxic for the organism.


Anabolic Steroid Anabolic Agent Premature Ventricular Beat Sympathomimetic Agent Doping Method 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Antonaccio MJ (1980) Farmacologia clinica cardiovascolare. Martinucci EdGoogle Scholar
  2. 2.
    Appleby M, Eischer M, Martin M (1994) Myocardial infarction, hyperkalemia and ventricular tachicardia in young male body builder. J Cardiol 44:171–174Google Scholar
  3. 3.
    Bruno M (1990) Gli steroidi anabolizzanti ed il loro abuso nella pratica sportiva Clin Ter 135:159–72PubMedGoogle Scholar
  4. 4.
    Celotti F, Negri-Cesi P (1992) Anabolic Steroids. J Steroid Biochem Mol Biol 43:469–11PubMedCrossRefGoogle Scholar
  5. 5.
    Cheever K, House Ma (1992) Cardiovascular implication of anabolic Steroid abuse. J Cardiovasc Nurs 6:19–30PubMedGoogle Scholar
  6. 6.
    Di Biase G, Labriola E (1966) Le catecolamine e Papparato cardiovascolare. Patrou EdGoogle Scholar
  7. 7.
    Ferenchick GS (1991) Anabolic/androgenic Steroid abusewith cardiomyopaty in atlet. Am J Med 92:562CrossRefGoogle Scholar
  8. 8.
    Ferenchick GS (1991) Anabolic/andogenic Steroid abuse and thrombosis, is there a connection? Med Hypotheses 35:27PubMedCrossRefGoogle Scholar
  9. 9.
    Haupt HA (1993) Anabolic Steroid and growth hormone. Am J Sport Med 21:468–74CrossRefGoogle Scholar
  10. 10.
    Katz AM (1981) Fisiologia del cuore. Cortina EdGoogle Scholar
  11. 11.
    Kennedy MC, Lawrence C (1993) Anabolic Steroid abuse and cardiac death. Med J Aust 158:346–8PubMedGoogle Scholar
  12. 12.
    Jensen LK (1994) Biviz Kninger oy dopingcontrol Ved lrug of anabolic Steroid. Vgeskr-Laeger 156:58723–3Google Scholar
  13. 13.
    Luke JL et al (1990) Sudden cardiac death during exercise in a weight-ligter using anabolic Steroids. J Forensic Sei 35:1441–7Google Scholar
  14. 14.
    Schimd P (1990) Der Einsatz von Beta-Rezeptors-Blockern in Leistungssport. Wien Med Wochenschr 140:184–8Google Scholar
  15. 15.
    Smith DA, Perry PJ (1992) The efficacy of ergonogenic agents in athletic competition. Ann Pharmacother 26:520–8PubMedGoogle Scholar
  16. 16.
    Thomson PD et al (1992) Left ventricular funetion is not impaired in weightlifters who use anabolic Steroids. J Am Coli Cardiol 9:278–82CrossRefGoogle Scholar
  17. 17.
    Venerando A, Zeppilli P (1982) Cardiologia dello sport. Masson EdGoogle Scholar
  18. 18.
    Vecchiet L, Calligaris A, Montanari G, Resina A (1990) Trattato di medicina dello sport applicata al calcio. Menarini EdGoogle Scholar
  19. 19.
    Weider AA, Melchert RE (1993) Cardiotoxiceffects of cocaine and anabolic-androgenic Steroids in the athlete. J Pharmacol-Toxical Methods 29:61–8CrossRefGoogle Scholar
  20. 20.
    Zeppilli. Cuore d’atleta. Master Pharma EdGoogle Scholar
  21. 21.
    Zinzen E, Clariys JP, Vanderstappen D, Vandenberg YJ (1994) The influence of triazolam and flunitruzepam an isokinetic and isometri muscle Performance Ergonomics 37:69–77CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1997

Authors and Affiliations

  • C. Montemartini
    • 1
  • G. Iraghi
    • 1
  1. 1.Divisione di CardiologiaIRCCS Policlinico S.MatteoPaviaItaly

Personalised recommendations